Author Archives: Joana Carvalho

Transition from PDE5i to Adempas Without Washout Period Deemed Safe

Transition from phosphodiesterase-5 inhibitors (PDE5i) — such as United Therapeutics’ Adcirca (taladafil) and Pfizer‘s Revatio (sildenafil) — to Bayer‘s Adempas (riociguat), a soluble guanylate cyclase (sGC) stimulator, without a washout period is a viable option for some patients with pulmonary hypertension, a small study suggests. The…

Inspiratory Muscle Weakness Aggravates Shortness of Breath in CTEPH Patients, Study Shows

Inspiratory muscle weakness aggravates shortness of breath caused by exertion and lung function capacity in patients with chronic thromboembolic pulmonary hypertension, a study has found. The study, “Inspiratory muscle weakness contributes to exertional dyspnea in chronic thromboembolic pulmonary hypertension,” was published in the journal PLOS One. CTEPH is a…